Bundibugyo Ebola outbreak in DR Congo outstrips response capacity as first vaccine trials begin
The WHO warns the epidemic is the largest ever recorded in the country, with over 3,800 confirmed cases and 1,700 deaths, while two candidate vaccines enter Phase I human testing.
The Bundibugyo Ebola outbreak in the Democratic Republic of the Congo has expanded beyond the capacity of the health response, the World Health Organization said on Tuesday, making it the largest such epidemic the country has ever faced. As of early August, 3,802 confirmed cases and 1,707 deaths had been recorded across five provinces, with nearly 90 per cent of cases concentrated in the northeastern Ituri province. More than 17,000 contacts are under surveillance, and over 80 per cent receive daily check-ups. “The outbreak is unfortunately still expanding beyond the capacity of the response,” WHO spokesman Tarik Jasarevic told reporters in Geneva, calling for more financial and operational support to scale up treatment, field investigation, safe burial teams and community health workers.
No vaccine, treatment or post-exposure prophylaxis has been proven safe and effective against the Bundibugyo species driving the epidemic, which was declared on 15 May. Two front-running vaccine candidates have now entered Phase I trials. A ChAdOx1-vectored vaccine developed by the University of Oxford and the Serum Institute of India began dosing volunteers in the United Kingdom on 24 July. A separate mRNA-based candidate from Moderna started a Phase I study in Canada this week, with plans to enrol 80 healthy adults at sites in Nova Scotia and Ontario to assess safety, dosage and antibody responses. Health Canada authorised the trial on 30 July, and the first volunteer received a dose on Monday in Truro, Nova Scotia.
In parallel, a WHO-sponsored treatment trial is under way at three clinical sites in Ituri, where more than 50 patients with confirmed Ebola have been randomly assigned to receive the monoclonal antibody MBP134, the antiviral remdesivir, or a combination of the two. A separate prophylaxis study, led by the DRC’s National Institute of Biomedical Research, has enrolled more than 25 high-risk contacts to test whether a 10-day course of the oral antiviral obeldesivir can prevent disease after exposure. Vasee Moorthy, acting head of the WHO’s R&D Blueprint, said early pre-clinical data were promising but cautioned that only the clinical trials could determine efficacy.
Response efforts remain hampered by armed conflict, population displacement and community mistrust, with nearly 80 per cent of new cases arising from unidentified transmission chains rather than contact tracing, according to Africa CDC. The WHO is also reviewing animal data on whether the licensed Ervebo vaccine, which targets the Zaire species, offers cross-protection against Bundibugyo. A WHO vaccine advisory group examined the findings last week and is expected to publish its recommendations in the coming days.
| Latin American press | −0.20 | neutral |
|---|---|---|
| Atlantic / Anglosphere press | −0.40 | critical |
| Arab Levant-Maghreb press | 0.00 | neutral |
| Russian & CIS press | −0.30 | critical |
Latin America braces to contain the Ebola threat, tightening port controls and following WHO guidelines, while the Congo battles an uncontrolled epidemic.
The mechanism localizes the threat in Africa and projects the response as a national defense measure, creating an implicit hierarchy between a dangerous 'elsewhere' and a protected 'here'.
The context of violence and community mistrust hindering the response, present in the Atlantic bloc materials, is omitted.
The West watches with alarm the Ebola escalation in Congo, highlighting the lack of vaccines and local mistrust as factors aggravating an already out-of-control crisis.
The mechanism emphasizes the symmetry between the speed of contagion and the ineffectiveness of the response, creating a sense of urgency and helplessness.
The detail of progress in clinical trials of drugs and vaccines, present in the Arab Levant-Maghreb bloc materials, is omitted.
The international community, through the WHO, calls for resources to stop Ebola in Congo, while researchers cautiously advance clinical trials.
The mechanism universalizes the crisis as a global problem requiring a coordinated response, dampening alarm with scientific data and realistic timelines.
The mention of violence and community mistrust as specific obstacles, present in the Atlantic bloc, is omitted.
Russia reports the epidemic numbers in Congo with detachment, citing the WHO as the authority calling for resources, without emphasizing the role of Western powers.
The mechanism personifies the Russian state as a neutral observer recording facts, avoiding moral judgments or emotional involvement, and aligns with the WHO's call for help.
The detail that 80% of new cases come from community spread, present in the Latin American and Atlantic materials, is omitted.
Broaden your view
US Senate votes 86-11 to advance Russia sanctions bill authorising 100% tariffs on top energy buyers
10 languages · 40 outlets
From Economy & MarketsUS imposes 15% tariff and price floors on polysilicon to counter China’s supply-chain dominance
4 languages · 16 outlets
From TechnologyIndia cuts AI-content takedown deadline to three hours after Meta row
2 languages · 8 outlets